Press Release

PhRMA Statement on Brazil Cotton Dispute

PhRMA April 30, 2013

Washington, D.C. (March 9, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) President, International, Christopher A. Singer issued the following statement today regarding the issuance of the final cotton dispute goods retaliation list by Brazil:

“Upon review of the retaliation list issued by Brazil in the cotton dispute we find that there are products listed made by PhRMA member companies. We are disappointed that Brazil has gone down this path as pharmaceutical companies have no stake in this dispute or the US cotton program.

However, we are encouraged by the statement that Secretary of State Hilary Clinton made last week that the US government intends to meet with Brazilian officials to find a mutually agreeable, expeditious solution to this problem.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit:

For information on the danger of imported drugs, visit: